Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2699 - Factors influencing the use of thromboprophylaxis in cancer outpatients: CAT AXIS, a case-vignette study on clinical practice.


10 Sep 2017


Poster display session


Supportive Care and Symptom Management


Florian Scotté


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


F. Scotté1, I. Elalamy2, D. Mayeur3, G. Meyer4

Author affiliations

  • 1 Medical Oncology And Supportive Care Unit, Foch Hospital, 92 - Suresnes/FR
  • 2 Biological Hematology, Inserm U938, Paris, France, Tenon University Hospital,, Paris/FR
  • 3 Medical Oncology, Centre Hospitalier de Versailles - Hopital Andre Mignot, 78157 - Le Chesnay/FR
  • 4 Pneumology, Hopital European George Pompidou, 75015 - Paris/FR


Abstract 2699


Data on long-term venous thromboembolism (VTE) prophylaxis in cancer outpatients remain scarce. In the absence of consistent treatment guidelines, our objective was to describe clinical practice and to identify factors influencing the use of thromboprophylaxis.


CAT AXIS was a multicenter cross-sectional study based on the completion of physician-profile questionnaires and the assessment of 10 e-mailed credible clinical scenarios of lung, colon and breast cancer by each of participants using the case-vignettes validated method.


A total of 224 physicians participated allowing the completion and the analysis of 2,085 case vignettes corresponding to 765, 703 and 617 fictive clinical scenarios on lung, colon and breast cancers, respectively. The overall rate of thromboprophylaxis was 680/2085 (32.6%) among participants with a comparable proportion for the three types of cancer. Low-molecular-weight heparin (LMWH) was the most frequently used, by 92.7%, 93.8% and 83.9% of participants for lung, colon and breast cancer, respectively; treatment duration of ≥ 3 months was prescribed by 74.4% of participants. Multivariate analysis of factors influencing thromboprophylaxis based on patient’s characteristics is summarized in Table.rnTable:

1562P Factors influencing the prescription of thromboprophylaxis

rnLung cancerColon cancerBreast cancer
OR [95% CI]pOR [95% CI]pOR [95% CI]p
ECOG index score: 3 vs 0-23.3 [2.4; 4.6]


In the absence of clear guidance, the use of thromboprophylaxis remains low and rather empiric even though the selection of LMWH by the majority of participants and treatment duration seems appropriate based on available data to date. ECOG index, metastatic malignancy, chemotherapy and history of thrombosis were significantly associated with the decision to use thromboprophylaxis in most situations.

Clinical trial identification

Legal entity responsible for the study

Guy Meyer


Leo Pharma


F. Scotté: Roche, Vifor, MSD, TEVA, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, AMGEN, Pierre Fabre Oncologie, TESARO D. Mayeur: Leo Pharma, Pfizer G. Meyer: Investigator (uncompensated) in clinical trials for: Daiichi Sankyo; Bayer; Sanofi Aventis; Leo Pharm; BMS-Pfizer, Daiichi Sankyo; Boehringer-Ingelheim, Bayer All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.